title: [ICD leads].
abstract: Implantable cardioverter-defibrillator (ICD) leads have to fulfill particular requirements: safe pacing and sensing, detection, and termination of ventricular tachyarrhythmias, if necessary by (multiple) high-energy shocks. At the same time, their implantation has to be simple, they need to provide excellent long-term stability and they must be completely and safely extractable. Numerous technical developments have enabled currently available ICD leads to fulfill these expectations to a high extent. However, some changes of lead design, materials, and manufacturing processes have led to increased lead failure, especially in two lead models (Medtronic Sprint Fidelis®, St. Jude Medical Riata®). The high rate of lead failure was identified only several years after market release, in part because there are no appropriate registries of ICD leads. This review presents background and developments of ICD lead technology and their association with the clinical usage of ICD therapy. To also benefit patients with only slightly-to-moderately increased risk of ventricular tachyarrhythmia, optimum ICD therapy requires optimal leads and sufficiently experienced implanters.
authors.affiliation: Klinik für Innere Medizin - Kardiologie, Diabetologie & Nephrologie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland, Carsten.Israel@evkb.de.
authors.forename: Carsten W
authors.initials: CW
authors.lastname: Israel
authors.forename: Mohamed Karim
authors.initials: MK
authors.lastname: Sheta
mesh_terms: D017147:Defibrillators, Implantable; D004553:Electric Conductivity; D004867:Equipment Design; D004868:Equipment Failure; D019544:Equipment Failure Analysis; D004869:Equipment Safety; D019317:Evidence-Based Medicine; D006801:Humans; D019919:Prosthesis Implantation / Q000379:methods*; D017180:Tachycardia, Ventricular / Q000517:prevention & control*; D013673:Technology Assessment, Biomedical